paclitaxel
Paclitaxel is a drug used to treat Breast Cancer, Ovarian Cancer, Lung Cancer, and other conditions. Paclitaxel is being actively studied in 536 studies and prior, has been studied in 879.
Top Sponsors | Top Sites | Top Investigators |
---|---|---|
National Cancer Institute (NCI) | Fox Chase Cancer Center | Zefen Xiao |
Hoffmann-La Roche | University of Oklahoma Health Sciences Center | Zhimin Shao |
M.D. Anderson Cancer Center | Washington University School of Medicine | H.W.M. van Laarhoven |
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
S
Not yet recruiting
- Ovarian Cancer
- albumin-bound paclitaxel
- paclitaxel
- (no location specified)
2022-03-31
Mar 31, 2022C
Not yet recruiting
- Breast Cancer
- doxorubicin
- +6 more
- Beijing, Beijing, ChinaCancer Hospital, ChineseAMS
2022-03-17
Mar 17, 2022C
Recruiting
- Ovarian Cancer
- +3 more
- chiauranib
- +2 more
- Shanghai, ChinaFudan University Shanghai Cancer Center
2022-03-07
Mar 7, 2022S
Terminated
- Carcinoma, Non-Small-Cell Lung
- Napabucasin
- Paclitaxel
- Beverly Hills, California
- +4 more
2022-04-04
Apr 4, 2022U
Recruiting
- Breast Cancer
- Paclitaxel
- Ann Arbor, MichiganUniversity of Michigan Rogel Cancer Center
2022-02-01
Feb 1, 2022U
Active, not recruiting
- Breast Neoplasm Female
- Paclitaxel
- Madison, WisconsinUniversity of Wisconsin Carbone Cancer Center
2022-01-10
Jan 10, 2022U
Active, not recruiting
- Breast Cancer
- +3 more
- Paclitaxel
- Alisertib
- Including Dallas And Austin, Texas22 Sites
2021-12-03
Dec 3, 2021W
Recruiting
- Cutaneous Angiosarcoma
- Paclitaxel
- +2 more
- Saint Louis, MissouriWashington University School of Medicine
2021-05-25
May 25, 2021S
Recruiting
- Triple-Negative Breast Cancer
- EndoTAG-1
- +2 more
- Kaohsiung, Taiwan
- +5 more
2022-02-18
Feb 18, 2022A
Active, not recruiting
- Triple Negative Metastatic Breast Cancer
- +3 more
- KU-0059436 (AZD2281)(PARP inhibitor)
- +3 more
- Brussels, Belgium
- +2 more
2022-03-02
Mar 2, 2022N
Recruiting
- Locally Advanced Malignant Solid Neoplasm
- +2 more
- Capecitabine
- +6 more
- Bethesda, MarylandNational Cancer Institute Developmental Therapeutics Clinic
2022-03-17
Mar 17, 2022S
Recruiting
- Stomach Neoplasms
- +2 more
- Paclitaxel
- Seoul, Korea, Republic ofGastric cancer center, Seoul St. Mary's Hospital
2021-07-01
Jul 1, 2021A
Active, not recruiting
- Breast - Female
- Male Breast Cancer
- Pembrolizumab
- Paclitaxel
- Charlotte, North CarolinaLevine Cancer Institute
2021-12-14
Dec 14, 2021D
Active, not recruiting
- Advanced Gastric Cancer
- Paclitaxel
- +2 more
- Seoul, Korea, Republic ofSeoul National University Hospital
2021-09-22
Sep 22, 2021U
Active, not recruiting
- Triple Negative Breast Cancer
- Carboplatin
- +3 more
- Chicago, IllinoisUniversity of Illinois
2022-01-28
Jan 28, 2022S
Recruiting
- Solid Tumor
- Stomach Cancer
- Alpelisib
- Paclitaxel
- Seongnam-si, Gyeonggi-do, Korea, Republic of
- +1 more
2021-08-21
Aug 21, 2021A
Active, not recruiting
- Gastric Cancer
- olaparib
- +2 more
- Anyang, Korea, Republic of
- +13 more
2022-04-05
Apr 5, 2022W
Active, not recruiting
- Transitional Cell Carcinoma
- Laboratory Biomarker Analysis
- +2 more
- Winston-Salem, North CarolinaWake Forest University Health Sciences
2021-08-30
Aug 30, 2021E
Recruiting
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Rivoceranib
- Paclitaxel
- Seoul, Korea, Republic ofAsan Medical Center
2021-09-03
Sep 3, 2021H
Active, not recruiting
- Ovarian Cancer
- Pembrolizumab
- Paclitaxel
- Tampa, Florida
- +2 more
2022-03-17
Mar 17, 2022W
Recruiting
- Gastric Cancer
- +4 more
- Paclitaxel
- Lobaplatin
- Wuhan, Hubei, ChinaWuhan Union Hospital
2022-02-18
Feb 18, 2022N
Active, not recruiting
- Head and Neck Cancer
- carboplatin,
- +4 more
- Singapore, SingaporeNational Cancer Centre - Singapore
2021-09-06
Sep 6, 2021A
Active, not recruiting
- Advanced Breast Cancer
- Ribociclib (LEE011)
- Paclitaxel
- Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
2021-10-28
Oct 28, 2021E
No longer available
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Ramucirumab
- Paclitaxel
- (no location specified)
2022-04-06
Apr 6, 2022T
Completed
- Solid Tumor, Adult
- EOC202
- Paclitaxel
- Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
2022-03-30
Mar 30, 2022